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KPNA3 is a gene that has been linked to schizophrenia susceptibility.  In this study we 
investigated the possible association between KPNA3 variation and schizophrenia.  To 
investigate a wider role of KPNA3 across psychiatric disorders we also analysed major 
depression, PTSD, nicotine dependent, alcohol dependent and opiate dependent cohorts.  
Using a haplotype block-based gene-tagging approach we genotyped six KPNA3 single 
nucleotide polymorphisms (SNPs) in 157 schizophrenia patients, 121 post-traumatic stress 
disorder patients, 120 opiate dependent patients, 231 alcohol dependent patients, 147 nicotine 
dependent patients and 266 major depression patients.  One SNP rs2273816 was found to be 
significantly associated with schizophrenia, opiate dependence and alcohol dependence at the 
genotype and allele level.  Major depression was also associated with rs2273816 but only at 
the allele level.  Our study suggests that KPNA3 may contribute to the genetic susceptibility 
to schizophrenia as well as other psychiatric disorders.   
 





Karyopherin alpha-3 (KPNA3) encodes a 521 amino acid protein that is highly homologous 
to nuclear transport proteins including xenopus importin, yeast importin alpha 1 and human 
importin alpha 1.  The protein contains an N-terminal importin-beta-binding domain, 8 
armadillo repeats and a C-terminal acidic region which are common to importin-alphas [16].  
It is likely that karyopherins are responsible for the transport of macromolecules (containing 
nuclear import or export signals) between the nucleus and cytoplasm [24].   
The KPNA3 gene was mapped to 13q14.3 by fluorescence in situ hybridization analysis [32].  
Linkage studies have revealed this region to be of interest in schizophrenia susceptibility 
[3,9,21].  KPNA3 has been showed to be associated with schizophrenia in a British [37] and 
Chinese population [41].  The British study analysed 124 family trios consisting of mother, 
father and affected offspring and association with schizophrenia was found with three KPNA3 
polymorphisms including rs3736830, rs2181185 and rs626716 [37].  In the Chinese study 
investigating two KPNA3 polymorphisms, 238 family trios consisting of mother, father and 
affected offspring showed association with schizophrenia [41] and rs3782929 but not 
rs3736830.  In a Bulgarian population, association between KPNA3 and schizophrenia was 
not found [6].   
As well as being associated with schizophrenia, KPNA3 may also be associated with other 
psychiatric conditions as chromosome 13 overlaps a few psychiatric disorders.  A linkage 
scan has identified chromosome 13 of interest for alcohol and illicit drug dependence but this 
region does not overlap KPNA3 [2].  Other studies show that chromosome 13q14 is a 
susceptibility locus for mood disorder and bipolar disorder [19,23].  To date KPNA3 has not 
been analysed for association with other psychiatric disorders.  Other genes such as DRD2 
and DTNBP1 have been shown to be associated with a number of psychiatric conditions.  The 
DRD2 polymorphism rs6277 was first found to be associated with schizophrenia [18] but has 
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since found to be associated with working memory [40], alcohol dependence [28], 
impulsivity [38] and post traumatic stress disorder (PTSD) [34].  We have also established 
that a polymorphism in DTNBP1 (rs9370822) is common to a range of psychiatric conditions 
including schizophrenia [36], psychotic depression [12] and PTSD, nicotine dependence and 
opiate dependence [35].   
Schizophrenia is a complex multifactorial disorder, showing polygenic inheritance.  
Therefore to begin to understand the complexity of schizophrenia many polymorphisms in 
multiple genes need to be identified for association with disease and results validated.  We 
undertook our study to replicate the previous KPNA3 associations with schizophrenia in an 
Australian population and identify novel SNP associations.  To identify any common 
molecular mechanism across psychiatric disorders, we genotyped KPNA3 polymorphisms 
that were found significantly associated with schizophrenia in other cohorts including major 
depression, post-traumatic stress disorder (PTSD), alcohol dependent, nicotine dependent and 
opiate dependent groups.  This is the first study that has undertaken an analysis of KPNA3 
across a range of psychiatric disorders.  
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Materials and Methods 
Participants 
Controls 
The control group consisted of 237 unrelated Caucasians (98 female and 139 male) with a 
mean age of 36.8 years (s.d. ± 12.8 years).  The control group consisted of volunteers from 
the general public, hospital nursing and medical staff, and university staff and students.  
Formal screening for psychological disorders was not undertaken in the control population.  
As such the controls represent an unselected control group.  Controls were recruited in the 
Brisbane region (a city of approximately 2 million inhabitants on the East Coast of Australia) 
and all were of Caucasian descent.   
Schizophrenia 
The schizophrenia group consisted of 157 Caucasian patients.  Subjects were aged between 
18 and 65 years.  Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) 
diagnosis of schizophrenia was confirmed by at least two independent psychiatrists.  These 
patients had never been diagnosed with other psychiatric disorders, including schizoaffective 
disorder, major depressive episode with psychotic features, or bipolar disorder.  There were 
23 females and 134 males in the group diagnosed with schizophrenia with a mean age of 36.2 
years (s.d.  12.0 years).  The mean age of patients at first diagnosis (onset of psychotic 
symptoms) was 23.2 years (s.d.  7.3 years).  They were being treated at the Royal Brisbane 
and Women’s Hospital, The Park Psychiatric Unit, and the Valley Community Psychiatric 
Centre.  The clinical sample was composed of 65 inpatients and 92 outpatients. All patients 
were administered the Positive and Negative Symptom Scale (PANSS) [27] to assess severity 
of psychotic features.  The PANSS total mean score was 45.13, SD. 13.69.  This clinical 
sample was a group who had lived with schizophrenia for an average of 13 years since 
diagnosis and continued to experience positive and negative symptoms despite treatment with 
6  
antipsychotic medication.  Mean length of illness was 13.3 years, SD 10.6.  In addition the 
schizophrenia group contained a high proportion of individuals with a relatively severe 
history and/or a familial risk for psychosis. 
Opiate Dependence 
A total of 120 unrelated Caucasian participants (50 female and 70 male) diagnosed as opiate 
dependent were recruited for this study, all of whom were being assessed for naltrexone 
treatment as outpatients of the Hospital Alcohol and Drug Services Unit of the Royal 
Brisbane and Women’s Hospital.  Participants had a mean age of 30.0 years of age (s.d. ± 7.9 
years).  Approximately half of the participants were being managed on methadone prior to 
detoxification (47.2%) while the other half were on heroin (52.8%).  Those on methadone 
had a mean dose of 48.1 milligrams (s.d. 30.5), with a range between 10-165 milligrams.  The 
mean age of onset of heroin use was 22.4 years of age (s.d. 5.14), with a range between 15-43 
years.  Mean number of participant-reported detoxifications prior to this occasion was 3.5 
(s.d. 3.3), with a range between 0-16 detoxifications.  Cannabis was the most commonly 
concurrently used illicit substance reported by participants prior to treatment (52.5% reported 
use), followed by amphetamines (14.9% reported use).  Individuals were excluded from the 
study if they suffered from psychosis, depression or PTSD.  Individuals were not excluded 
from the study if they were smokers and approximately 90% were smokers.   
PTSD  
A total of 121 unrelated male Caucasian patients diagnosed with PTSD using Diagnostic and 
Statistical Manual of Mental Disorders-IV (DSM-IV) criteria were recruited through the 
Greenslopes Private Hospital for the study.  Participants had a mean age of 52 years of age 
(s.d.  6.2).  All subjects were Vietnam combat veterans who had served in the Australian 
Armed Forces.  None were being treated with psychotropic medications.  Patients were 
excluded from the study if they had a diagnosis of psychosis, bipolar disorder, obsessive 
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compulsive disorder, or organic brain syndrome including dementia.  Patients were excluded 
from the study if that had opiate dependence.  All subjects had sufficient comprehension of 
English and could understand the administered questionnaires. Patients were assessed for 
PTSD by a consultant psychiatrist or a senior psychiatric registrar using DSM-IV criteria.  
Furthermore, every patient exceeded the clinical cut-off score of 94 on the Mississippi Scale 
for combat-related PTSD [15].  Patient clinical history and demographic data including ethnic 
background were also obtained.  After the procedure had been fully explained, all participants 
provided written informed consent.  They were able to terminate their involvement at any 
time during the interview without prejudice.  Institutional ethics approval was obtained from 
the Greenslopes Private Hospital. 
Alcohol Dependence 
A total of 231 unrelated Caucasian (74 female and 157 male) alcohol dependent subjects 
were recruited from large public hospitals in Brisbane, Australia.  The mean age of the group 
was 40.74 years (s.d. ± 10.3 years).  All subjects were assessed against a checklist of specific 
criteria by a clinical psychologist experienced in drug and alcohol dependence and met DSM-
IV (Diagnostic and Statistical Manual of Mental Disorders IV) criteria of alcohol dependence 
disorder.  All were inpatients and represented a spectrum of severity with a significant 
proportion (n = 65) of these patients being diagnosed with two or more alcohol related 
medical conditions such as pancreatitis, cirrhosis, hepatitis or peripheral neuropathy.  Alcohol 
dependent patients were excluded from the study if they had dementia, delirium, psychosis, 
or any other condition that would affect their ability to provide informed consent.  A large 
proportion (81%) of the alcohol dependent cohort was also smokers.   
Nicotine Dependence 
A total of 147 (68 male, 79 female) unrelated Caucasians with a mean age of 43.3 (s.d. ± 11.1 
years) were recruited from large public hospitals in Brisbane, Australia.  Participants were 18 
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years of age or older and had smoked for at least three years and were generally healthy 
despite currently smoking 15 cigarettes or more per day.  Patients with other comorbid 
substance abuse disorders including alcohol and opiate dependence were excluded from the 
study.   One hundred and thirty nine of the participants were administered the Fagerstrom test 
for Nicotine Dependence [14].   
Major Depression 
A sample of 266 (113 male, 153 female) unrelated Caucasian patients with a current major 
depression (mean age 49.7 ±15.3 years) admitted for in-patient treatment were recruited at 
the Department of Psychiatry, University of Muenster, Germany.  Patients with 
schizoaffective disorders, bipolar disorder or comorbid substance abuse disorders, mental 
retardation, pregnancy and neurological, neurodegenerative disorders or other clinically 
unstable medical illnesses impairing psychiatric evaluation were not included in this analysis 
[4,11]. 
 
Ethics approval was obtained from all institutions involved and each participant gave written 
informed consent.  The study conforms with The Code of Ethics of the World Medical 
Association (Declaration of Helsinki), printed in the British Medical Journal (18 July 1964). 
 
Selection of SNPs 
Using the International HapMap project phase II (International HapMap, 2003), five tag-
SNPs in KPNA3 with a minor allele frequency cut-off of 0.15 were selected.  Tag-SNPs were 
identified using the pair-wise option of Tagger with a threshold of r2>0.8.  An additional non-
synonymous SNP was also chosen for analysis.  Using the Stampa algorithm it was 
calculated that 94.14% of the variation in the KNPA3 gene was captured using the five tag 
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SNPs (rs1407439, rs2273816, rs9562919, rs1923730, rs2236354) and one non-synonymous 
SNP (rs10450845) [13].   
Genotyping 
Oragene kits were used to extract DNA from saliva samples.  Samples were genotyped using 
a homogeneous MassEXTEND (hME) Sequenom assay performed by the Australian Genome 
Research Facility.  The hME assay is based on the annealing of an oligonucleotide primer 
(hME primer) adjacent to the SNP of interest.  The addition of a DNA polymerase along with 
a mixture of terminator nucleotides allows extension of the hME primer through the 
polymorphic site and generates allele-specific extension products, each having a unique 
molecular mass.  The resultant masses of the extension products are then analysed by matrix-
assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) and 
a genotype is assigned in real time.   
Statistical Analysis 
A Fisher’s exact test was performed to identify statistical associations between genotype and 
disease status.  A Pearson’s chi-squared test was performed to identify statistical associations 
between allele and disease status.  Odds ratios (OR) were also calculated.  Tests were 
performed on both genotype and allele data.  Statistical tests were performed using the 
COMPARE2 program from the WinPepi suite of epidemiology programs [1] and SPSS 
version 16.  Hardy-Weinberg equilibrium (HWE) was computed using Utility Programs for 
Analysis of Genetic Linkage [26].  Correction for multiple testing was conducted using the 
false detection rate (FDR) method [5].  Haplotypes were generated and analysed for linkage 




A comprehensive genotype analysis of KPNA3 and its association with schizophrenia was 
undertaken using a haplotype block-based gene-tagging approach.  A total of five tag-SNPs 
and one synonymous SNP that span from the 3'-end to the 5'-end of the gene were genotyped 
in a sample of 157 schizophrenia patients and 237 controls.  One SNP rs2273816 was found 
to be significantly (p = 0.003) associated with schizophrenia at the allele level (Table 1).  It 
was also significant at the genotype level (Table 3) and survived correction for multiple 
testing (FDR corrected α-value was 0.01).   
The attributable fraction of the rs2273816 polymorphism was calculated using genotypes 
counting the presence of the associated allele as a risk factor.  The attributable fraction, which 
is the proportion of cases in the study population that would not have occurred had the risk 
factor (risk allele) not have been present, is a useful measure to quantify the impact of the 
allele on the development of schizophrenia [17].  The analysis revealed that 15.56% (95% CI 
= 5.29-24.71%) of the susceptibility to schizophrenia could be attributed to having the GA 
genotype of the rs2273816 polymorphism.   
Haplotype analysis was completed and the results revealed no improvement in association 
with any haplotype combinations compared to the rs2273816 SNP analysed in isolation.  The 
best haplotype combination was with rs2273816 and rs9562919 (p=0.026).  Furthermore, the 
rs2273816 SNP showed low LD with all other SNPs while the other SNPs were in very high 
disequilibrium.   
Genotype frequencies indicated that all polymorphisms were in HWE in both schizophrenia 
and control samples. 
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Major Depression, PTSD, Nicotine dependence, Opiate Dependence and Alcohol 
dependence Genotyping 
To investigate the role of rs2273816 in a range of psychiatric conditions this SNP was 
genotyped in 266 unipolar major depression samples, 121 PTSD samples, 154 nicotine 
dependent samples, 120 opiate dependent samples and 231 alcohol dependent samples.  The 
rs2273816 SNP was found to be associated with alcohol dependence, opiate dependence and 
major depression at the allele level but not PTSD or nicotine dependence (Table 2).  At the 
genotype level rs2273816 was still associated with alcohol and opiate dependence but not 
major depression unless it was tested using the Mantel-Haenszel test for trend (Table 3).  
Individuals with alcohol or opiate dependence were more than twice as likely to carry the GA 
genotype compared to the control group.  Genotype frequencies indicated that rs2273816 was 
in HWE for all samples including controls, major depression, PTSD, nicotine dependent, 
opiate dependent and alcohol dependent samples.   
For the two groups, nicotine dependence and PTSD that did not show association, we did not 
have sufficient power (<0.80) to detect association with our sample sizes.   
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Discussion 
Schizophrenia is not a single disorder of uniform phenotype; it exists as a clinically variable 
spectrum of disease with some features that overlap other recognised psychiatric disorders.  
We therefore postulated that genes involved in schizophrenia like KPNA3 might also play a 
role in other disorders.  This is the first study to investigate an association between the 
KPNA3 gene and a range of psychiatric conditions.  KPNA3 has not been intensively 
investigated for a cross-disorder role in various psychiatric diseases even though it is situated 
in a region highly associated with schizophrenia risk.  Only two studies have shown that 
KPNA3 is associated with schizophrenia [37,41].  We sought to replicate these associations 
with KPNA3 and schizophrenia as well as investigate the role of KPNA3 in various 
psychiatric conditions in order to search for possible common pathways across psychiatric 
disorders.  In our study we found the KPNA3 SNP rs2273816 to be significantly associated 
with schizophrenia, opiate dependence and alcohol dependence at the genotype level.  Major 
depression was also associated with rs2273816 but only at the allele level.   
A British study also found rs22731816 to be associated with schizophrenia but only with 
rs3736830 as a haplotype [37].  They also found rs3736830 to be associated with disease on 
its own.  In our study we did not genotype the rs3736830 polymorphism.  Like our study, 
their sample size was also relatively small and this association needs to be replicated in a 
larger sample size and possibly different ethnic groups.  A Chinese study failed to find 
association with rs3736830 but this maybe because of ethnicity [41].  Genome Wide 
Association Studies (GWAS) have not found KPNA3 to be associated with schizophrenia 
[29-31].  However,  if KPNA3 confers small disease risk then it would be unlikely to be 
found using GWAS where the current P value threshold is 5 x 10-8 taking into account 
multiple testing [7,25].  Schizophrenia is a complex multifactorial disorder where genetic and 
environmental factors confer risk.  The genetic component is likely the result from numerous 
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polymorphisms in many genes that individually have a small effect.  It is now believed that 
rare polymorphisms that account for a large percentage of schizophrenia heritability will not 
be captured using GWAS [33,39].   
Interestingly, KPNA3 is also involved in the nuclear import of the influenza virus [22].  
Although not conclusive, evidence does suggest that gestational exposure to influenza 
contributes to the etiology of schizophrenia {reviewed [8]].  Therefore it is plausible that 
KPNA3 acts as a susceptibility gene for schizophrenia only after prenatal infection.  
Unfortunately we did not collect data on maternal exposure to infection.  To answer this 
question, schizophrenia patients that have been exposed to an infection including influenza 
would be genotyped for KPNA3 genetic variants.  It is unlikely that exposure to the influenza 
virus is involved in the etiology of alcohol and opiate dependence.  However like 
schizophrenia, exposure to the influenza virus may contribute to the etiology of major 
depression although to date there has been no evidence to support this.   
There are a number of possible limitations of this study.  Population stratification can 
produce false positive associations where the underlying structure of the population results in 
genetic differences in the frequency of variants rather than differences due to the presence of 
disease susceptibility alleles.  Every effort was made to ensure the uniformity of the 
population by selecting patients and controls of European descent however we cannot rule 
out population stratification and our results need to be confirmed independently in a 
Caucasian group as well as defined ethnic groups.  The best research practice is for an 
experienced mental health professional to perform a structured interview (SCID) to generate 
patient diagnosis.  A limitation of our study is that we did not perform a SCID except for the 
depression group.  However, we did ensure all participants met DSM1V criteria and were 
diagnosed by more than one experienced mental health professional.  The samples size of 
each psychiatric condition studied was relative small and requires replication in larger 
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independent patient groups.  Association was not detected for the nicotine dependent and 
PTSD groups.  The sample size was large enough to detect a strong genetic effect but to 
determine if these groups are also associated with KPNA3 variation with an OR less than 1.5, 
a population size of more than 700 patients for each group would be required to give 
sufficient power.  Our controls were not screened for a mental illness however, more 
significant associations are likely to be found using controls screened for a lack of mental 
illness.   
This is a preliminary study and requires replication in a larger sample cohort with defined 
psychiatric diagnoses.  Although many association studies often report conflicting results it is 
likely that many of these candidate associations independently have a minor effect on disease 
and may produce varied results depending on the severity of disease and the heterogeneity 
and ethnicity of the population.  It is possible that KPNA3 has a minor effect on the 
susceptibility to schizophrenia, major depression and substance misuse through a common 
molecular pathway.  It is not surprising that a common pathway across these psychiatric 
disorders may be involved since depression and substance misuse are often seen as comorbid 
conditions in patients with schizophrenia [20].   
Acknowledgements 
This work was financially supported by the Queensland State Government, the Nicol 
Foundation and the Institute of Health and Biomedical Innovation, QUT.  JV is a Queensland 










































































































































Table 1.  Allele association of 6 KPNA3 SNPs with schizophrenia 
* Nucleotide position on the chromosome 13 reference sequence 
† p-value determined by Pearson’s chi-squared test 
 
SNP ID Position* SNP details χ2 p-value† Odds Ratio  95% CI 
rs1407439 49181116 Intron 7 A/G 1.112 0.292 1.20 0.85-1.72 
rs2273816 49192057 Intron 5 A/G 8.924 0.003 1.96 1.22-3.15 
rs10450845 49205117 Asp61Asn Not polymorphic in this study 
rs9562919 49221809 Intron 1 A/T 0.748 0.387 1.14 0.84-1.54 
rs1923730 49229993 Intron 1 A/G 0.210 0.647 1.08 0.77-1.49 
rs2236354 49263967 Intron 1 C/T 0.275 0.600 1.09 0.78-1.52 
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Table 2.  Allele Association of KPNA3 SNP rs2273816 with multiple psychiatric conditions 
Sample set χ2 p-value* Odds Ratio 95% CI 
Schizophrenia 8.924 0.003 1.96 1.22-3.15 
PTSD 2.297 0.130 1.47 0.86-2.48 
Nicotine dependence 2.755 0.097 1.49 0.90-2.47 
Opiate dependence 6.036 0.014 1.82 1.09-3.03 
Alcohol dependence 7.916 0.005 1.81 1.17-2.84 
Major Depression 5.556 0.018 1.63 1.07-2.52 
 
* p-value determined by Pearson’s chi-squared test 
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Table 3.  Genotype Association of KPNA3 SNP rs2273816 
 
Sample Set Genotype Counts  p-value* 
 GG (%) GA (%) AA (%)  




Schizophrenia 102(69.39) 41(27.89) 4(2.72) 
Odds ratio 1 2.261 1.765  
p-value  0.004 0.863  
PTSD 89(74.79 29(24.37) 1(0.84) 0.074 
0.138† 
Odds ratio 1 1.833 0.506 
p-value  0.072 1.000  
Nicotine dependence 108(77.14) 27(19.29) 5(3.57) 0.307 
0.121† 
Odds ratio 1 1.406 2.083 
p-value  0.478 0.561  
Opiate dependence 81(70.43) 32(27.83) 2(1.74) 0.015 
0.017† 
Odds ratio 1 2.222 1.111 
p-value  0.010 1.000  
Alcohol dependence 148(71.15) 55(26.44) 5(2.41) 0.010 
0.006† 
Odds ratio 1 2.090 1.520 
p-value  0.005 1.000  
Major Depression 191(74.61) 57(22.27) 8(3.12) 0.066 
0.025† 
Odds ratio 1 1.679 1.885  
p-value  0.063 0.590  
* p-value determined by Fisher’s exact test as some cells have an expected frequency <5 
†p-value determined using the extended Mantel-Haenszel test for trend 
 
